Dr. Brian C. Myre, MD | Glen Ellyn, IL ...

Dr. Brian C. Myre

Claim this profile

Elmhurst Memorial Hospital

Studies Renal Cell Carcinoma
Studies Kidney Cancer
7 reported clinical trials
28 drugs studied

Affiliated Hospitals

Image of trial facility.
Elmhurst Memorial Hospital
Image of trial facility.
Edward Hospital/Cancer Center

Clinical Trials Brian C. Myre is currently running

Image of trial facility.

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
Image of trial facility.

Immunotherapy With or Without Surgery

for Kidney Cancer

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Recruiting2 awards Phase 316 criteria

More about Brian C. Myre

Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Brian C. Myre has experience with
  • Atezolizumab
  • Radiation Therapy
  • Ipilimumab
  • Nivolumab
  • Cisplatin
  • Apalutamide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Brian C. Myre specialize in?
Is Brian C. Myre currently recruiting for clinical trials?
Are there any treatments that Brian C. Myre has studied deeply?
What is the best way to schedule an appointment with Brian C. Myre?
What is the office address of Brian C. Myre?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security